Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

standing (000's) - basic and diluted 85,114 85,114 --------------------------------- --------------------------------------- a. One time payment from Baxter Healthcare Corporation in lieu of future royalty payments on licensed technology and non-recurring, non- operating license revenue. b. Non-recurring manufacturing variances, primarily related to excess labour costs incurred and to certain inventory write-downs resulting from cancellations of orders by a significant customer of our surgical needles business. Adjustments for the 2008 period relate to non-recurring supply / distribution agreement termination costs. c. Research and development adjustments: --------------------------------------------------------------------- Six months Six months ended ended Jun 30, 2009 Jun 30, 2008 ---------------------------- Stock-based compensation $ (215) $ (500) Termination and reorganization costs - (1,307) Non-recurring research and development expenses and intellectual property license agreement related to our termination agreements with Lipose Corp. and Spartan Medical Products LLC. (937) (1,125) --------------------------------------------------------------------- $ (1,152) $ (2,932) ---------------------------- d. Selling, general and administrative adjustments: ---------------------------------------------------------------------
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... LANSING, Mich. , July 7, 2015  Neogen ... has signed an agreement to expand its relationship with ... sequencing and genomics. Under the agreement, Illumina will market ... on Illumina Infinium ® BeadArray technology, to the ... Illumina,s largest agrigenomic customers through its GeneSeek ® ...
(Date:7/7/2015)... , ... July 07, 2015 , ... ... driven community in the biometrical area. What began as a conference for European ... community for various functions in the biometrical area. Statistical Programmers, Data Managers and ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... Institute (WPI), offers new insights into how virulent fungi adapt through genetic modifications ... and how that battle leaves them temporarily weakened. These insights may provide clues ...
(Date:7/6/2015)... , June 29, 2015 ... has announced the addition of the "Biotechnology ... Biotechnology for the Non-Biotechnologist, ideal for ... theory, principles, techniques and potential of biotechnology. ... understand the basic theory, principles, techniques, and potential ...
Breaking Biology Technology:Neogen signs commercialization agreement with Illumina 2PhUSE Delighted to Welcome Member Number 5.000 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4
... Amnis Corporation and Gene Company, Ltd.,announced today ... Company,will sell and service the Amnis ImageStream(R) system ... Hong Kong, Shanghai,Beijing and Guangzhou now have access ... extremely pleased to have begun what we expect ...
... and Company) (NYSE: BDX ), a global medical technology company,announced ... Bank of America 2008 Healthcare Conference ... Bernstein 24th Annual Strategic Decisions Conference 2008 ... A live webcast of BD,s presentations can be accessed from the ...
... May 7 /PRNewswire-FirstCall/ Varian, Inc. (NasdaqGS:,VARI) announced that ... Glover,as a new director. Glover is the seventh ... appointed for a term expiring at the annual ... is Senior Vice President, Operations and Chief Financial ...
Cached Biology Technology:Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China 2James T. Glover Appointed to Board of Directors of Varian, Inc. 2
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... in behaviour among the population have accelerated the recent decline ... in Science shows how there has been an almost 50 ... researchers attribute to people delaying when they first have sex ... fell most steeply at young ages, with a drop in ...
... one of the oldest healing remedies known to medicine, ... A review article in the most recent issue of ... the data. , Scientists performed 22 trials involving 2,062 ... 16 trials that were performed on experimental animals. Honey ...
... created in this cool movie , ,Scientists ... created polymer nanotubes that are unusually long (about 1 centimeter) ... Described in a new paper in Proceedings of the National ... as channels for tiny volumes of chemicals in nanofluidic reactor ...
Cached Biology News:HIV decline in Zimbabwe linked to behavioural change 2Stable polymer nanotubes may have a biotech future 2
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: